Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase a (PI3Ka) inhibitors are in clinical development. The activity of these agents, however, is not homogeneous, and only a fraction of patients bearing PIK3CA-mutant ER-positive tumors benefit from single-agent administration. Searching for mechanisms of resistance, we observed that suppression of PI3K signaling results in induction of ER-dependent transcriptional activity, as demonstrated by changes in expression of genes containing ER-binding sites and increased occupancy by the ER of promoter regions of upregulated genes. Furthermore, expression of ESR1 mRNA and ER protein were also increased upon PI3K inhibition. These changes in gene expression were confirmed in vivo in xenografts and patient-derived models and in tumors from patients undergoing treatment with the PI3Ka inhibitor BYL719. The observed effects on transcription were enhanced by the addition of estradiol and suppressed by the anti-ER therapies fulvestrant and tamoxifen. Fulvestrant markedly sensitized ER-positive tumors to PI3Ka inhibition, resulting in major tumor regressions in vivo. We propose that increased ER transcriptional activity may be a reactive mechanism that limits the activity of PI3K inhibitors and that combined PI3K and ER inhibition is a rational approach to target these tumors.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) pathway is essential for cell growth, proliferation, survival, and metabolism (1, 2) . The PI3K family of enzymes is divided into three main classes (I to III), with class I being the most often implicated in human cancer (3) . Members of the class IA PI3K are characterized by a heterodimer composed of a catalytic subunit (p110a, b, and d) and a regulatory subunit (p85) (4, 5) . PIK3CA, the gene coding for p110a, is frequently mutated in human cancers (6, 7) . In particular, hotspot mutations of this gene that reside in the helical (E542K and E545K) or catalytic (H1047R) domains are found in over a third of estrogen receptor (ER)-positive breast cancer, representing the most common genomic alteration in this group of tumors (7, 8) .
Selective PI3K p110a (PI3Ka) inhibitors are currently being tested in the clinic in patients with advanced malignancies, with promising results in patients with breast tumors harboring PIK3CA mutations (9, 10) . However, not all the patients benefit equally from these agents, and even those that initially respond typically relapse after months of therapy.
Although we have recently reported that the emergence of resistant clones with genomic alterations that activate PI3Kb may partially explain acquired resistance to PI3Ka inhibitors (11) , alternative mechanisms may also be at play in primary or early resistance to these therapies. Among them, activation of alternative cellular compensatory pathways could explain primary resistance or the emergence of rapid resistance. For example, we have shown that pharmacological suppression of mammalian target of rapamycin (mTOR), which is downstream from PI3K and a central node within the PI3K/AKT/mTOR axis, results in activation of both AKT (12) and extracellular signal-regulated kinases (ERK) (13) and can account for decreased efficacy of mTOR inhibitors. Similarly, inhibition of PI3K leads to compensatory activation of upstream receptor tyrosine kinases that limit the effectiveness of these compounds (14, 15) .
Given that the vast majority of PIK3CA-mutant tumors are ERpositive, it is plausible to hypothesize that both pathways can drive proliferation and survival in these cells. A tangible evidence that the PI3K and ER pathways can cooperate in tumor progression came from a clinical study (16) that showed an impressive improvement in progression-free survival in ER-positive breast cancer patients treated with the mTOR inhibitor everolimus in combination with the antiestrogen aromatase inhibitor exemestane. These patients had failed previous endocrine therapy, and considering that activity of singleagent mTOR inhibitors is minimal, these results suggest a synergistic activity in targeting mTOR and ER signaling simultaneously. Nevertheless, little is known about the reciprocal regulation of these key pathways, although it has been described that chronic anti-estrogen therapy induces the activation of the PI3K pathway in vitro (17, 18) . Perhaps more relevant to our interest in understanding the effects of PI3K inhibition on ER signaling, studies in prostate cancer have convincingly shown that the PI3K pathway regulates androgen receptor activity (19) .
On the basis of all these observations, our work was aimed at studying the effects of PI3Ka inhibition on ER signaling and at deciphering its potential effect on limiting the efficacy of PI3K inhibitors. We report that inhibition of the PI3K pathway triggers the activation of the ERdependent transcription machinery. The importance of this adaptive response is underscored by the finding that suppression of ER activity can sensitize tumors to PI3K inhibition.
RESULTS

PI3K inhibition promotes ER activity
To obtain a comprehensive view of the role of PI3K activation in modulating ER function, we examined the effects of pharmacological PI3K inhibition in ER-positive breast cancer cells that harbor activating PIK3CA mutations (MCF7-E545K and T47D-H1047R). Previous studies have established that a large portion of the transcriptome in these cells is regulated by ER activity (20) , so they were a good model to explore whether PI3K inhibition had any effect on ER-regulated genes. Cells were treated with the highly selective PI3Ka inhibitor BYL719 at 1 mM for 4, 8, 12, 24, or 48 hours, and cellular lysates were analyzed. As measured by intensity of phosphorylation of AKT (S473) and S6 (S235/6), BYL719 caused potent inhibition of PI3K signaling as early as 4 hours after drug exposure and lasting for 48 hours, with a slight rebound in activity observed at the 48-hour time point ( fig. S1 ).
We observed that at this concentration, BYL719 also induced global changes in the transcription profile of both MCF7 and T47D cells. Perturbations in their gene expression profiles were evident 12 hours after the addition of BYL719 to the culture medium and were sustained until at least 48 hours (Fig. 1A and fig. S2 , respectively). Strikingly, of the 383 and 706 genes significantly altered upon BYL719 treatment in MCF7 and T47D cells [false discovery rate (FDR) ≤ 1%], respectively, up to 60% contained an estrogen-responsive element (ERE) in their promoter (Fig. 1B) . Gene Set Enrichment Analysis (GSEA) was conducted on the genes altered by PI3K inhibition and demonstrated that gene sets characterized by ER dependence were highly enriched in this group (FDR ≤ 25%) (Fig. 1C, fig. S3 , and table S1). On the basis of these findings, we next decided to confirm the relationship between PI3K activity and ER transcriptional activity by analyzing the effects of drug inhibition on promoters known to be stimulated by estrogen. First, we examined the effect of BYL719 treatment on expression of a luciferase transgene linked to a 3X-ERE promoter. Sixteen hours after treatment, an about twofold higher luminescence was detected in the BYL719-treated cells than in the dimethyl sulfoxide (DMSO)-treated cells (Fig. 1D) .
We next used polymerase chain reaction (PCR) to confirm that drug treatment had an effect on the expression of endogenous mRNAs known to be regulated by ER, including progesterone receptor (PGR), growth regulation by estrogen in breast cancer 1 (GREB1), and insulinlike growth factor-binding protein 4 (IGFBP4) (Fig. 1E) . The increased expression was due, at least in part, to ER transcriptional activity, because ChIP-qPCR (quantitative PCR) experiments showed a two-to threefold enhancement in occupancy by ER of the promoter regions of these up-regulated genes (Fig. 1F) . Together, our findings demonstrate that inhibition of activated PI3K signaling present in PIK3CA-mutant ER-positive breast cancer cells is associated with an increase in the transcriptional function of the ER.
In addition to PIK3CA mutations, there are other genetic mechanisms that also result in aberrant PI3K pathway signaling. Specifically, phosphatase and tensin homolog (PTEN) function is lost in a subset of ER-positive tumors (21) . Unlike PIK3CA mutation, PTEN loss appears to activate phosphatidylinositol 3,4,5-trisphosphate (PIP 3 )/ AKT signaling preferentially through the p110b subunit, and PI3Ka-selective inhibitors do not inhibit PI3K/AKT signaling in these cells (22) . Because AKT is downstream from PI3K, we used MK2206, a selective AKT inhibitor, in CAMA1 cells (PTEN mut D92H) ( fig. S4 ) to test whether inhibition of the PI3K pathway promoted ER activation in an ER-positive PTEN-mutant model. Similar to MCF7 and T47D cells treated with BYL719, suppression of AKT in CAMA1 cells resulted in an overall increased expression of ER-dependent genes and in the induction of an ER-dependent signature ( fig. S5 and table S2 ). The activation of ER as a consequence of PI3K pathway inhibition in the context of PTEN null/mut tumors was further corroborated by assessing the effect of the AKT inhibitor MK2206 on PGR and GREB1 expression by qPCR in CAMA1, ZR-75-1, and MDA-MB-415 cells ( fig.  S6 ). Overall, the findings observed in both PTEN-and PIK3CA-mutant ER-positive breast cancer models are similar and demonstrate an increased ER-dependent transcription activity upon inhibition of the PI3K pathway by different strategies.
PI3K inhibition increases ER expression
As mentioned above, we found that inhibition of PI3K promotes ER activity, as manifested by increases in ER binding to target promoters and increases in ER target gene expression. We speculated that ER expression itself might also be increased in response to PI3K inhibition and might partially explain the increases in ER activity. We examined ESR1 mRNA expression in a panel of ER-positive breast cancer cell lines (Fig. 2, A and B, and fig. S7 ) and found increases ranging from 1.5× to 3× upon PI3K inhibition with BYL719, with maximal accumulation observed at 24 hours in the MCF7 model. Coinciding with the initial rise in mRNA (8 hours), RNA polymerase II binding to the ESR1 promoter was observed to be increased about twofold by ChIP assay ( fig. S8) . A similar induction of the ESR1 transcript was observed with various PI3K inhibitors (GDC0032, GDC0941, BAY80-6946, and BKM120) in ER-positive/PIK3CA-mutant models ( fig. S9 ). The increase in ESR1 mRNA coincided with increases in the ER protein, which was also maximal at about 24 hours over a 48-hour time course (Fig. 2B) . Comparing the effects of PI3K inhibition with mTORC1 (mTOR complex 1) inhibition on ESR1 regulation, we observed an appreciable increase in the expression of ESR1 and its target genes also during rapamycin treatment, albeit with a lower magnitude compared to BYL719 ( fig.  S10) . Together, the data show an increase in ER expression as a result of PI3K inhibition in various cell culture systems. To determine whether increases in ER expression and activity might be observed in vivo, we used a noninvasive probe of ER expression, 16a-18 F-fluoro-17b-estradiol positron emission tomography ( 18 F-FES-PET). This probe measures uptake of labeled estradiol (E 2 ) as an indirect measure of ER expression. In T47D xenografts, we observed a selective increase in tumor uptake of 18 F-FES in mice treated with BYL719 compared to those receiving vehicle (Fig. 2C) . Although such differences could be due to other mechanisms, such as changes in tumor retention time or receptor affinity for E 2 , they are consistent with the findings of increased expression of the receptor observed in vitro (Fig. 2, A and B, and figs. S7 to S9).
To assess the clinical relevance of our findings, we analyzed the gene expression profiles of tumor samples collected from patients treated with BYL719 as part of either the first-in-human clinical trial (9) or an ongoing clinical study testing the efficacy of BYL719 in combination with the aromatase inhibitors letrozole or exemestane (NCT01870505). Paired tumor biopsies were collected from patients before commencing BYL719 therapy and after a minimum of 14 days on treatment, between 4 and 6 hours after the daily drug administration. Two patients were treated with BYL719 as a single agent, and eight patients were treated with the combination of BYL719 and an aromatase inhibitor. Table S3 shows the patients' information, including breast tumor histology at diagnosis, PIK3CA mutation status, BYL719 dose, and the treatment in combination with BYL719 (if any). Notably, either as single agent or in combination, BYL719 was administered at clinically active doses in all cases (11, 23) .
The expression of 105 breast cancer-related genes, including the genes from the prediction analysis of microarray 50 (PAM50) intrinsic subtype predictor (24) , was compared across the 20 paired biopsies. Thirty-nine genes were differentially expressed (FDR ≤ 25%; Table 1 ). Not surprisingly, proliferation-related genes such as MKI67, BIRC5, and CENPF were among the most highly down-regulated genes in the on-treatment samples, whereas the antiapoptotic genes BCL2 and MDM2 were up-regulated. Central to our work, ESR1 and its target gene PGR were among the most highly induced genes upon PI3K inhibition ( Table 1 ). The ESR1 transcript levels were shown to increase during PI3K inhibition in all but two patients evaluated (Fig. 2D ). In accordance with this result, a switch from a non-luminal A phenotype [luminal B or human epidermal growth factor receptor 2 (HER2)-enriched] in the pretreatment sample to a luminal A subtype in the on-treatment sample was identified by the PAM50 subtype predictor in three (patients 1, 4, and 6) of the six patients (patients 1, 3, 4, 6, 9, and 10) who showed the highest increase in ESR1 (table S3) . There was a global shift in the transcriptional profile of the tumors toward a more luminal A-like signature across all "on-treatment" samples (Fig. 2E) . Notably, the pretreatment sample from patient 2 was already identified as luminal A; however, we observed a higher expression of the luminal A signature in the on-treatment sample compared to the pretreatment sample. Furthermore, patient 9 presented a change in intrinsic subtype from basal-like in the pretreatment sample to luminal B in the ontreatment biopsy, which was accompanied by the highest increase in ESR1 expression (Fig. 2, D and E). Although these are small numbers of patients, the data support the idea that ER mRNA increases upon PI3K inhibition, in conjunction with a more estrogen-dependent luminal A phenotype.
In an attempt to identify the mechanisms responsible for the observed increase in ESR1 transcription upon PI3Ka inhibition, we hypothesized that the expression and/or activity of transcription factors known to bind the promoter of ESR1 were augmented under these conditions. Hence, we investigated the possible role of forkhead box O3 (FOXO3A), a transcription factor known to be regulated by PI3K/AKT signaling, in regulating ER expression. We found that inhibition of PI3K with BYL719 led to a >5× accumulation of FOXO3A at the ESR1 promoter by ChIP assay (Fig. 2F) . To determine whether the induction of FOXO3A binding was necessary for the increase in ESR1 mRNA, we used small interfering RNA (siRNA) to knock down FOXO3A in MCF7 cells and found that the loss of FOXO3A prevented the induction of ESR1 caused by BYL719 (Fig. 2G) . These data suggest that FOXO3A is necessary for the effect of PI3K inhibition upon ESR1 expression.
PI3K inhibition-induced ER activity is enhanced by the presence of ligand The effects of ER on breast cancer progression are thought to be dependent on both ligand-dependent and ligand-independent mechanisms (25, 26) . Because these different modes of activation have implications for the optimal means of pharmacologic inhibition of ER, we investigated whether the induction of ER activity required the presence of E 2 . MCF7 cells were grown in medium depleted of steroidal hormones (charcoal-stripped serum) for 48 hours and then treated with DMSO (vehicle), BYL719, E 2 , or the combination of BYL719 and E 2 for 4 hours, and ChIP assays were performed. As expected, the addition of E 2 increased ER binding to the PGR and GREB1 promoters about threefold compared to control cells not exposed to E 2 . In the presence of E 2 , 1 mM BYL719 caused further enhancement of binding two-to threefold over E 2 alone (Fig. 3, A and B) . However, in the absence of E 2 , BYL719 caused a much smaller enhancement of binding (1.2× to 1.5×) over untreated cells. Similarly, when we examined the effect of PI3K inhibition on transcription of PGR and GREB1, we again found that addition of E 2 or the combination of E 2 and BYL719 promoted PGR and GREB1 accumulation. However, BYL719 treatment in the absence of E 2 caused very little increase in PGR or GREB1 after 0 to 16 hours of drug exposure (Fig. 3C) . We next analyzed the effects of the ER antagonists 4-hydroxytamoxifen (4-OHT) and fulvestrant by qPCR. Under normal serum conditions, both 4-OHT (1 mM) and fulvestrant (100 nM) attenuated the expression of ER target genes with no impact on ESR1 mRNA (fig. S11 ). The same inhibitors were sufficient to prevent BYL719-mediated increased expression of the four tested ER target genes (Fig. 3D and fig. S12 ). These data suggest that blockade of estrogen function mitigates the effects mediated by PI3K inhibition.
PI3K inhibition in combination with ER inhibitor fulvestrant has profound antitumor activity in ER/PIK3CA mut models Because fulvestrant was the most potent antagonist of PI3K inhibitorinduced ER activity, we chose to use this agent to characterize the biologic consequences of the ER induction. We used two well-established ER-positive/PIK3CA mut xenograft models (MCF7 and T47D cells) to test the combination. Daily administration of BYL719 (25 mg/kg) resulted in modest reduction of tumor growth in both models (Fig. 4A  and fig. S13 ). Fulvestrant monotherapy (200 mg/kg, twice weekly) was sufficient to prevent further tumor growth and, in some cases, to induce tumor shrinkage. However, the combination of both agents showed marked tumor regression and, in some cases, resulted in complete tumor remissions. Consistent with a tumor cell-autonomous effect of the combination, fulvestrant and BYL719 in combination potently inhibited cell cycle progression in MCF7 cells in vitro ( fig.  S14 ). Not only were these effects seen in cell line-derived xenograft models but also when we further investigated the effects of these treatments in a patient-derived xenograft (PDX) model of ER-positive PIK3CA mut (H1047R) breast cancer (Fig. 4B) . Notably, this PDX was established from a patient who had previously progressed on multiple lines of endocrine therapy, including fulvestrant. In this model, the combination of BYL719 and fulvestrant induced partial tumor regression, despite very limited single-agent activity for either BYL719 or fulvestrant. To confirm that the lack of tumor regressions from single-agent BYL719 was not due to failure of the drug to inhibit the target in vivo, we collected a set of MCF7 xenografts for analysis after 4 days of treatment. BYL719 effectively inhibited pAKT (S473), as well as phosphorylation of the ribosomal protein S6, a downstream effector of S6K, indicative of a therapeutic dose of BYL719 (Fig. 4C) . Moreover, ER protein expression showed a marked increase with BYL719 treatment that was mitigated by the addition of fulvestrant.
Finally, to confirm our observations that ER activity is induced by the PI3K inhibitor in vivo, gene expression analysis was conducted on a representative cohort of the PDX and MCF7 xenografts. Tumors were collected after short-term treatment (4 to 7 days), and gene expression profiling revealed that BYL719 significantly varied the expression of 190 genes (FDR ≤ 1%) in the PDX models, 61% of which have an ER-binding site in their promoter (Fig. 4D) . This translated to enrichment for an ER-dependent signature, as confirmed with GSEA (Fig. 4E) . A similar enrichment in the ER-dependent signature was seen in the treated MCF7 tumors (Fig. 4F) . Together, these data indicate that the increase in ER expression and function mediated by PI3K suppression attenuates the benefit of the PI3K inhibitor, and strongly suggest that combinations of PI3K and ER inhibitors should be tested in the clinic.
DISCUSSION
Here, we show that inhibition of the PI3K pathway in ER-positive breast cancer results in induction of ER-dependent transcriptional activity. These effects on the transcriptome were not restricted to a few selected ER target genes but rather expression of hundreds of genes controlled by EREcontaining promoters. The causative role of ER in rewiring gene expression upon PI3K inhibition was underscored by its complete prevention when fulvestrant, a direct ER antagonist, was added to the system. These observations led us to consider whether one of the mechanisms for up-regulation of ER signaling was augmentation of ER itself. This indeed proved to be the case, and we found a consistent increase in ER transcript and induction of a luminal signature (typical of hormoneresponsive breast cancers) in cell lines, murine models, and patient samples upon suppression of the PI3K pathway. However, it remains to be elucidated whether this increase in ER expression is the sole factor responsible for the induction of ER activity after PI3K inhibition.
This increase in ER transcription is likely to be an adaptive response to the inhibition of the PI3K pathway. Indeed, we and others have shown that nongenetic activation of compensatory pathways is frequently observed in response to a variety of targeted therapies and that it may limit their efficacy (12) (13) (14) (15) . We surmise that the compensatory activation of ER-dependent genes occurring early upon PI3K inhibition decreases the antitumor efficacy of PI3K inhibitors. This may explain the limited activity of PI3K inhibitors when used as monotherapy in patients with ER-positive breast cancer and suggests that simultaneous ER suppression would be a logical strategy to combine with PI3K inhibition. The clinical activity observed in ER-positive patients treated with the combination of the mTOR inhibitor everolimus and an aromatase inhibitor (16) , as well as very early clinical data with PI3Ka inhibitors in combination with other anti-estrogen agents (27) (28) (29) seem to support this hypothesis. Consistent with our PDX data, these clinical studies indicate that dual PI3K and ER blockade is effective even in patients who had progressed on previous anti-estrogen therapies.
We are aware that our findings have certain limitations. We have not tested the ligand dependency of ER in vivo, mainly because of a lack of preclinical models of aromatase inhibition, a standard of care in postmenopausal women. Moreover, we acknowledge that the clinical validation of our findings would benefit from a larger cohort of patients treated with PI3K inhibitors than the one used in this work. The requirement of paired pretreatment and on-treatment samples to study acute changes in gene expression, however, limits the number of patients suitable for these analyses. This is a caveat that should be taken into consideration at the time of designing clinical trials, where mandatory on-treatment biopsies could provide important information on early adaptive response to therapy.
Reflecting on our findings, one cannot escape from drawing a parallel with prostate cancer, where a reciprocal feedback regulation of PI3K and androgen receptor (AR) activity has been recently described (19) . In the case of prostate cancer, inhibition of the PI3K pathway results in activation of AR and, conversely, blockade of AR activates PI3K signaling. This bidirectional crosstalk seems to also occur in the breast where, in addition to our findings showing ER activation upon PI3K inhibition, inactivation of ER appears to be associated with activation of PI3K signaling (18, 30) . This speaks for a true interdependency between these two pathways, where a state of equilibrium between PI3K and ER signaling is reached to ensure cell survival. Thus, both prostate and breast cancer cells may adapt to suppression of the PI3K pathway by increasing their dependence on the hormone receptor function. Fig. 3 . PI3K inhibitor-mediated induction of hormone signaling is dependent on E 2 and ER. MCF7 cells were treated with BYL719 (1 mM), E 2 (10 nM), or the combination after 48 hours in estrogen-free medium. ChIP was performed with anti-ERa antibody or control IgG. (A and B) Primers to amplify the ER-binding regions of the PGR (A) and GREB1 (B) promoters were used in qPCR to determine fold enrichment relative to input. One-way ANOVA statistical test was used to compare mean signal amplification between each treatment and vehicle-treated samples, applying the Bonferroni method to correct for multiple comparisons. Error bars represent SEM of two independent experiments with three technical replicates each. (C) MCF7 cells were preincubated for 48 hours in steroid hormone-depleted medium and subsequently treated with BYL719 (1 mM), E 2 (10 nM), or the combination over a period of 16 hours, and RNA was isolated at the indicated times. qPCR was performed to detect bACTIN, PGR, and GREB1 expression. The data are presented relative to bACTIN and to expression at time 0 in the BYL719-treated samples. One-way ANOVA statistical test was used to compare gene expression between each treatment and vehicle-treated cells, applying the Bonferroni method to correct for multiple comparisons. The results presented are for the comparisons at the 16-hour time point. Error bars denote SEM of two independent experiments with three technical replicates each. (D) MCF7 cells, grown under normal serum conditions, were treated with BYL719 (1 mM), alone or in combination with 4-OHT (1 mM) or fulvestrant (FULV) (100 nM) over a period of 16 hours. mRNA was isolated at the indicated times. qPCR was performed to detect bACTIN, PGR, and GREB1 expression. The data are presented relative to bACTIN and to expression at time 0 in the vehicle-treated samples. One-way ANOVA statistical test was used to compare gene expression between each treatment and vehicle-treated cells, applying the Bonferroni method to correct for multiple comparisons. The analysis results presented are for the comparisons at the 16-hour time point. Error bars denote SEM of two independent experiments with three technical replicates each. mut PDX mice, which were treated with either vehicle or BYL719 with the same dosing and schedule as described in (B). Mice were sacrificed, and tumors were obtained on day 4, 2 hours after the last dose, and processed to obtain RNA for microarray gene expression analysis. Graph represents genes whose expression differed significantly across different treatments with an FDR ≤1%. Each of the columns under the experimental conditions represents one biological replicate. Venn diagram represents differentially regulated genes upon treatment with BYL719 (SAM analysis FDR ≤ 1%) and the percentage of these that contained an ERbinding site, defined by ER ChIP-sequencing data available from (40) . (E) GSEA analysis was performed to determine which gene sets were enriched in the PDX microarray expression data set obtained in (D). Graph represents enrichment for ER-associated signature (FDR ≤ 25%) as described in (42) . (F) Pharmacodynamic studies on the MCF7 xenografts from (A) were performed on day 7 of treatment by means of a punch biopsy in both vehicle-and BYL719-treated mice. A representative number of biopsies (at least two biological replicates per condition) was processed to obtain RNA and submitted for gene expression analysis. GSEA was performed to determine which gene sets were enriched in our data set (FDR ≤ 25%). Graph represents enrichment for ER-associated signature as described in (42) .
In our hands, ER degradation by fulvestrant treatment was more effective than the ER modulator 4-OHT for resensitizing tumors to PI3K inhibitors. A plausible explanation for these results is that ER degradation may potentially prevent both the estrogen-dependent and estrogen-independent activities (31, 32) mediated by PI3K inhibition. However, further studies will be required to confirm which of the currently available anti-estrogen therapies, if any, is superior when given in combination with PI3K inhibitors.
In summary, our results suggest that PI3K blockade in ER-positive breast cancer triggers an ER-dependent transcriptional program that ultimately may be reversed with ER-targeting therapies. Thus, simultaneous blockade of PI3K and ER may be needed for optimal treatment of ER-positive breast tumors with aberrant activation of the PI3K pathway.
MATERIALS AND METHODS
Study design
The aim of our study was to explore the mechanism by which the combination of PI3K pathway inhibitors and ER function blockade results in superior antitumor activity. We aimed to evaluate whether changes in ER function were influencing the clinical response to anti-PI3K therapy in ER-positive breast tumors that harbor PI3K pathway activation. For this purpose, we planned to use various specific PI3K inhibitors, namely, BYL719 (p110a-specific catalytic inhibitor), GDC0941 and BKM120 (pan-PI3K inhibitors), and GDC0032 and BAY80-6946 (p110b-sparing PI3K inhibitors) in a panel of ER-positive breast cancer cell lines and xenografts that harbor PIK3CA activating mutations. We also used MK2206 (pan-AKT allosteric inhibitor) to inhibit the PI3K pathway in ERpositive cell lines that activate this pathway through PTEN loss. Finally, to evaluate the role of ER up-regulation as a prosurvival signal in our in vitro and in vivo models, we planned to use the selective ER modulator 4-OHT and the degrader fulvestrant. For the in vivo experiments, the number of animals in each group was calculated to measure a 25% difference between the means of placebo and treatment groups with a power of 80% and a P value of 0.01. Host mice carrying xenografts were randomly and equally assigned to either control or treatment groups. Animal experiments were conducted in a controlled and nonblinded manner. We also used RNAseq to evaluate gene expression changes in breast cancer patients who underwent BYL719-based therapy to validate our in vitro findings on ER expression. In vitro experiments were performed at least two times and at least in triplicate.
Plasmids pRL-TK Renilla luciferase plasmid was obtained from Promega, and 3X-ERE-TATA firefly-luciferase reporter was obtained from Addgene 
Establishment of tumor xenografts and in vivo treatments
All mouse studies were conducted through Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital Cancer Center, and Vall d'Hebron Institute of Oncology Institutional Animal Care and Use Committees approved animal protocols in accordance with institutional guidelines. Six-week-old female athymic nude mice were purchased from Charles River Laboratories and housed in air-filtered laminar flow cabinets with a 12-hour light cycle and food and water ad libitum. The size of the animal groups was calculated to measure a difference of means of 25% between placebo and treatment groups with a power of 80% and a P value of 0.01. Host mice carrying xenografts were randomly assigned to either control or treatment groups. Animal experiments were conducted in a nonblinded manner. For cell line-derived xenograft studies, mice were injected subcutaneously with 1 × 10 7 MCF7 or T47D suspended in 150 ml of culture medium/Matrigel (BD Biosciences) in a 1:1 ratio. For PDXs, patient consent for tumor use in animals was obtained under a protocol approved by the Vall d'Hebron Hospital Clinical Investigation Ethical Committee and Animal Use Committee. PDXs were derived from an ER-positive PR-positive HER2-negative breast cancer patient previously treated with both chemotherapy (taxanes and vinorelbine) and anti-endocrine therapy (exemestane and fulvestrant). Tumors (~2 × 2-mm size) were subcutaneously implanted in 6-week-old female HsdCpb:NMRI-Foxn1 nu mice (Harlan Laboratories). All animals were supplemented with 1 mM 17b-E 2 (Sigma) in their drinking water as described (34) .
Once tumors reached an average volume of~75 to 250 mm 3 , mice were randomized into treatment arms, with n = 7 to 10 tumors per group. BYL719 was dissolved in 0.5% carboxymethylcellulose solution and administered once daily via oral gavage at 25 mg/kg. Fulvestrant was diluted in castor oil and administered subcutaneously twice weekly at 200 mg/kg. Tumors were measured by digital caliper twice per week over the entire treatment period and, where indicated, harvested 2 hours after the last drug administration. Tumor volume was determined using the following formula: (length × width 2 ) × (p/6). Tumor volumes are plotted as means ± SEM. mRNA nCounter gene expression procedure A section of the formalin-fixed paraffin-embedded (FFPE) breast tissue was first examined with hematoxylin and eosin staining to determine the tumor surface area and cellularity. For RNA purification (Roche High Pure FFPET RNA Isolation Kit), one to three 10-mm FFPE slides were cut for each tumor, and macrodissection was performed, when needed, to avoid normal breast contamination. A minimum of~100 ng of total RNA was used to measure the expression of 105 breast cancer-related genes and 5 housekeeping genes using the nCounter platform (NanoString Technologies) (35) . Data were log 2 -transformed and normalized using five housekeeping genes (ACTB, MRPL19, PSMC4, RPLP0, and SF3A1). Raw gene expression data for patient samples were deposited in Gene Expression Omnibus (GSE63579).
The list of 105 genes includes genes from the following three signatures: PAM50 intrinsic subtype predictor (n = 50) (24), Claudin-low subtype predictor (n = 43) (36), and 13-VEGF/Hypoxia signature (n = 13) (37) . In addition, we included eight individual genes that have been found to play an important role in breast cancer (CD24, CRYAB, ERBB4, PIK3CA, PTEN, RAD17, RAD50, and RB1). All tumors were assigned to an intrinsic molecular subtype of breast cancer (luminal A, luminal B, HER2-enriched, basal-like, or the normal-like group) using the previously reported PAM50 subtype predictor (24) .
Analyses of microarray and mRNA nCounter gene expression data Illumina IDAT files were preprocessed using the IlluminaExpressionFileCreator module on GenePattern (www.broad.mit.edu/cancer/ software/genepattern). Supervised analysis to find genes associated with PI3K pathway inhibition treatments was performed using SAM (38) . The multiclass unpaired or the two-class paired method of SAM was used to identify genes whose expression differed significantly among treatments and/or time points. FDR was set as less than or equal to 1% for microarray-based analysis or to 25% for nCounter-based analysis. GSEA was used to determine the extent to which expression profiles were enriched for a priori defined sets of genes from biologically coherent pathways (39) . GSEA was performed using version 2.0 of GSEA run on all the gene sets in version 2.5 of the Molecular Signatures Database and to correct for multiple hypotheses testing; the FDR threshold was set at ≤0. 25 . A list of the specific signatures used for graphical representation and their specific description has been added to the Excel file with raw data (table S4) .
Statistical analysis
Statistical analysis for in vitro and in vivo experiments was performed using GraphPad Prism (GraphPad Software). When comparing two groups (control versus treated), two-tailed Student's unpaired t test was performed (significance level set at P < 0.05). When comparing various groups, one-way ANOVA statistical test was used, applying the Bonferroni method to correct for multiple comparisons. Independent experiments were conducted with a minimum of two biological replicates per condition to allow for statistical comparison. Error bars represent the SEM, and P values are indicated. All cellular experiments were repeated at least two times. For ChIP analysis (Fig. 1F) , the data are presented as fold enrichment relative to bACTIN as a control gene region. . Decreased expression of ER target genes after anti-ER therapy, with no effect on ESR1 mRNA. Fig. S12 . Up-regulation of ER target genes reversed by combining BYL719 with anti-ER treatment. Fig. S13 . Better tumor control in vivo after combining BYL719 with fulvestrant. Fig. S14 . Analysis of the effect of PI3Ka inhibition alone or with anti-ER therapy on the cell cycle. Table S1 . GSEA to assess ER-dependent signatures enriched in MCF7 cells treated with BYL719. Table S2 . GSEA to assess ER-dependent signatures enriched in CAMA1 cells treated with MK2206. Table S3 . Clinical and pathologic features corresponding to paired pretreatment and BYL719-treated tumor samples. Table S4 . Raw data (provided as an Excel file). References (43) (44) (45) 
